Find all the news of Anergis.

News

13 Dec 2018	Anergis Reports Positive Preclinical Proof-of Concept Data of the Second-Generation COP Allergy Vaccine
12 Dec 2018	Publication of "Designing trials for allergy product development" in Mednous
05 Sep 2018	Anergis Initiates Development of Second-Generation COP Allergy Vaccines; Announces Publication of Sustained Efficacy Data from Ph. IIb Study Follow-up
23 Apr 2018	Anergis and Mymetics Start Research Collaboration Project on the use of Virosomes for Ultra-Fast Allergy Immunotherapy
07 Sep 2017	Anergis Announces Top Line Results from Large-Scale ATIBAR Trial with Ultra-Fast Allergy Immunotherapy AllerT
13 Jun 2017	T-cell responses after COP Immunotherapy to be Presented at EAACI Congress 2017
01 Mar 2017	Anergis to Present Dose-Dependent Immunological Effects of Ultra-Fast Allergy Immunotherapy AllerT at the AAAAI annual meeting
08 Feb 2017	Anergis Completes Patient Recruitment in Large-Scale ATIBAR Trial with Ultra-Fast Allergy Immunotherapy AllerT
24 Jan 2017	Anergis Appoints Klaus Schollmeier as New Chairman of the Board of Directors
07 Jun 2016	Anergis to Present New Data on AllerT at the 35th EAACI Congress 2016

Page 1 of 5